Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma

Blood (2024) 144 (4): 402–407.

https://doi.org/10.1182/blood.2023023557

Published: 2024

Includes: Supplemental data

Journal Articles

A Comparative Analysis of Infectious Complications in Patients with Multiple Myeloma Treated with BCMA-Targeted Bispecific Antibodies and CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2023-179413

Published: 2023

Journal Articles

Molecular Monitoring with Tumor DNA and Nivolumab Maintenance: A Pilot Study in Diffuse Large B-Cell Lymphoma

Shazia Nakhoda, Tamarrah Sklarz, Cheyenne Pagan, Matthew Matasar, Marcus Messmer, Zachary AK Frosch, Y. Lynn Wang, Asya Varshavsky Yanovsky, Rashmi Khanal, Carlyn Rose Tan, Henry C. Fung, Eli Mikkelsen, Kevin A. David, Mark Roschewski, Eric Ross, Allison P. Jacob, Erin Ahn, Nadia Khan

Blood (2023) 142 (Supplement 1): 6231.

https://doi.org/10.1182/blood-2023-179980

Published: 2023

Journal Articles

Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy

Blood (2023) 142 (Supplement 1): 1961.

https://doi.org/10.1182/blood-2023-180283

Published: 2023

Journal Articles

Real-World Patient Profile and Step-up Dosing Process of Early Initiators of Teclistamab for Multiple Myeloma in US Hospitals - an Updated Analysis Using Premier Healthcare Database

Carlyn Rose Tan, Nina Kim, Eric Chinaeke, Laura Hester, Jessica Fowler, Dina Gifkins, Dee Lin, Sian Walker, Alex Z. Fu, Bingcao Wu

Blood (2023) 142 (Supplement 1): 3792.

https://doi.org/10.1182/blood-2023-178896

Published: 2023

Journal Articles

Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients

Blood (2023) 142 (Supplement 1): 3370.

https://doi.org/10.1182/blood-2023-187891

Published: 2023

Journal Articles

T-Cell Exhaustion Signature Predicts Early Relapse after Autologous Stem Cell Transplant for Multiple Myeloma: BMT CTN 0702 Secondary Immune Analysis

Nezar Mehanna, Andriy Derkach, Billel Gasmi, Theodora Anagnostou, Heather Landau, Oscar Boutros Lahoud, Michael Scordo, Gunjan L. Shah, Hani Hassoun, Kylee H Maclachlan, Malin Hultcrantz, Neha Korde, Sham Mailankody, Urvi A Shah, Carlyn Rose Tan, Saad Z Usmani, Sergio A. Giralt, Alexander Lesokhin, David Chung

Blood (2023) 142 (Supplement 1): 3326.

https://doi.org/10.1182/blood-2023-177960

Published: 2023

Journal Articles

Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas

Stefan K. Barta, MD MRCP, MS, Nathan H. Fowler, MD, Jasmine Zain, MD, Jia Ruan, MD PhD, Sonali M. Smith, MD, Stephen J. Schuster, MD, Sunita D Nasta, MD, Jakub Svoboda, MD, James N Gerson, MD, Daniel J. Landsburg, MD, Elise A. Chong, MD, Henry C. Fung, FRCP,MBBChir, Kerry S Campbell, PhD, Nadia Khan, MD, Richard I. Fisher, MD, Carlyn Rose Tan, MD

Blood (2019) 134 (Supplement_1): 4031.

https://doi.org/10.1182/blood-2019-125385

Published: 2019

Journal Articles

A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Carlyn Rose Tan, MD, Stefan K. Barta, MD MRCP, MS, Shelly Y. Lensing, Ariela Noy, MD

Blood (2019) 134 (Supplement_1): 1595.

https://doi.org/10.1182/blood-2019-129702

Published: 2019

Journal Articles

Brentuximab Vedotin with R-CHP Chemotherapy As Frontline Treatment for Patients with CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Grey Zone Lymphomas: Results of a Phase I/II Multisite Trial

Jakub Svoboda, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Stefan Klaus Barta, MDMRCP,MS, Nadia Khan, MD, Henry C. Fung, FRCP,MBBChir, Carlyn Rose Tan, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Lauren Elizabeth Strelec, BA, Sarah J. Nagle, Steven M. Bair, MD, Sheryl Mitnick, MPH, RN, Terease S. Waite, PhD RN, MBE, Rachel Lynn Sargent, MD, Agata M. Bogusz, MDPhD, Ziver Sahin, MD, Anthony R. Mato, MD, Stephen J. Schuster, MD

Blood (2017) 130 (Supplement 1): 191.

https://doi.org/10.1182/blood.V130.Suppl_1.191.191

Published: 2017

NARROW

Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma

A Comparative Analysis of Infectious Complications in Patients with Multiple Myeloma Treated with BCMA-Targeted Bispecific Antibodies and CAR T-Cell Therapy

Molecular Monitoring with Tumor DNA and Nivolumab Maintenance: A Pilot Study in Diffuse Large B-Cell Lymphoma

Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy

Real-World Patient Profile and Step-up Dosing Process of Early Initiators of Teclistamab for Multiple Myeloma in US Hospitals - an Updated Analysis Using Premier Healthcare Database

Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients

T-Cell Exhaustion Signature Predicts Early Relapse after Autologous Stem Cell Transplant for Multiple Myeloma: BMT CTN 0702 Secondary Immune Analysis

Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas

A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Brentuximab Vedotin with R-CHP Chemotherapy As Frontline Treatment for Patients with CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Grey Zone Lymphomas: Results of a Phase I/II Multisite Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only